More than a year after the original acquisition bid was announced, and months of acrimonious legal wrangling, USA-based Abbott (NYSE: ABT) is to proceed with the purchase of Alere (NYSE: ALR), but on revised terms.
Under the amended terms, Abbott will pay $51 per common share (versus the earlier $56) to acquire Alere, for a new expected equity value of around $5.3 billion, reduced from the originally expected equity value of about $5.8 billion.
Alere’s share price closed at $42.31 on Thursday, ahead of today’s formal joint announcement by Abbott and Alere.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze